Parkinson's Archives

News and Trends 31 May 2022

Award to help NRG Therapeutics develop new Parkinson’s and Motor Neuron Disease treatments

UK neuroscience company NRG Therapeutics Ltd has received a Biomedical Catalyst (BMC) award to fund preclinical development of its small molecule disease-modifying medicines for the treatment of Parkinson’s disease, motor neuron disease (MND) and other debilitating chronic neurodegenerative disorders. The £2.68M ($5.8M) early-stage BMC award part-funded by the government-backed agency Innovate UK will support a […]

May 31, 2022 - 3 minutesmins - By Jim Cornall

Discovering New Therapeutic Targets for Alzheimer’s Disease

Effective therapies for neurodegenerative diseases like Alzheimer’s are urgently needed. But developing new drugs is difficult, time-consuming, and expensive, with a high risk of failure. Strategic partnerships can help biotech companies manage costs and access the latest technologies to drive innovation and advance novel therapy ideas. A serious unmet medical need Finding treatments for neurodegenerative […]

September 22, 2021 - 7 minutesmins - By Julia Kaiser

News and Trends 12 Aug 2021

European Biotechs Fire up Deals to Develop Parkinson’s Treatments

Last month, European biotechs Ipsen and AC Immune announced multi-million euro deals to acquire or license treatments for Parkinson’s disease. For some experts, this increasing interest in the brain disease with the fastest growing prevalence is long overdue. In July, Swiss company AC Immune bought assets and intellectual property for investigational Parkinson’s vaccines valued at […]

August 12, 2021 - 4 minutesmins - By Anita Chakraverty

In Depth 22 Mar 2021

Can Immunotherapy Offer Hope for Parkinson’s Sufferers?

Despite decades of research, effective treatments for Parkinson’s disease are proving elusive. Could immunotherapy finally provide a solution? More than seven million people worldwide are currently living with Parkinson’s disease, an incurable neurodegenerative disorder. Current treatment options are limited as they only attempt to mask the symptoms rather than address the cause. But there is […]

March 22, 2021 - 5 minutesmins - By David Cox

parkinsons disease treefrog therapeutics cell therapy

News and Trends 9 Jun 2020

French Manufacturing Plant Launches to Make Cell Therapy Cheap and Scalable

The Bordeaux-based company Treefrog Therapeutics has opened an industrial demonstration plant with the aim of producing cell therapies 10 times more efficiently than with current technology. The €2M plant occupies an area around a fifth of the size of a football field and is expected to produce 80 billion cells per year when it reaches […]

June 9, 2020 - 4 minutesmins - By Jonathan Smith

More News! 27 Jun 2019

German Biotech Will Target Parkinsonian Disorders with €12M Series A

Modag has developed a candidate drug targeting the neurodegenerative disease multiple system atrophy, which it plans to take to the clinic with €12M in Series A funds. Multiple system atrophy is a rare disorder, with similar symptoms to Parkinson’s disease, that is caused by breakdown of neurons in parts of the brain. The German biotech’s […]

June 27, 2019 - 2 minutesmins - By Helen Albert

treefrog therapeutics cell therapy parkinsons disease

News and Trends 13 May 2019

Cell Encapsulation Biotech Raises €7M to Target Cell Therapy Bottlenecks

The French company Treefrog Therapeutics has raised over €7M in Series A investment to develop its encapsulation technology to improve the production of stem cells for cell therapies. Part of the Series A money will help Treefrog to automate its stem cell production process by 2021. The round will also fund the development of a […]

May 13, 2019 - 3 minutesmins - By Jonathan Smith

mission therapeutics abbvie parkinsons disease

More News! 16 Nov 2018

AbbVie Enters Industry Collaboration to Fight Alzheimer’s and Parkinson’s Disease

The UK biotech Mission Therapeutics has teamed up with AbbVie to develop new drugs to treat the neurodegenerative conditions Alzheimer’s disease and Parkinson’s disease. The new collaboration aims to fund the preclinical development of drugs that inhibit proteins called deubiquitinating enzymes. Deubiquitinating enzymes modify proteins in the cell, controlling essential functions such as what the […]

November 16, 2018 - 2 minutesmins - By Jonathan Smith

united neuroscience parkinsons disease cover

News and Trends 14 Nov 2018

Parkinson’s Disease Vaccine Shows Preclinical Promise

The biotech company United Neuroscience has developed a candidate Parkinson’s disease vaccine that targets a protein linked to the condition. The vaccine teaches the immune system to attack aggregations of alpha-synuclein. When this protein aggregates in neurons, it can lead to several neurodegenerative disorders, including Parkinson’s. In United Neuroscience’s preclinical study, the vaccine was able to prevent the […]

November 14, 2018 - 2 minutesmins - By Jonathan Smith

axovant parkinsons disease neuron dopamine

News and Trends 25 Oct 2018

Parkinson’s Disease Gene Therapy Clinical Trial Launched in UK

A gene therapy for Parkinson’s disease developed by Swiss biotech Axovant has been used on the first patient in a Phase I/II trial at University College London. Parkinson’s disease is a neurodegenerative disease, caused by a lack of the neurochemical dopamine in regions of the brain handling motor functions causing debilitating symptoms such as rigidity […]

October 25, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 9 Aug 2018

Modulating the Microbiome Could Boost Vaccine Performance

Dutch scientists have found that altering a patient’s microbiome with antibiotics before a vaccination can boost the body’s resulting immune response against rotavirus infection. Rotavirus causes severe vomiting and diarrhea and largely affects children. Over 200,000 children are killed by the virus each year. The rotavirus vaccine is made of weakened strains of the rotavirus, […]

August 9, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 25 Jun 2018

Cambridge Biotech Raises €32M Series A Round to Treat Chronic Inflammation

NodThera raised £28M (€32M) in a Series A round co-led by Sofinnova Partners and 5AM Ventures to develop treatments for chronic inflammation. NodThera, based in Cambridge, UK, closed a substantial Series A financing round to develop its lead small molecule drug candidate to treat inflammatory diseases, as well as other drugs for neurodegenerative diseases and […]

June 25, 2018 - 2 minutesmins - By Alexander Burik

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us